行情

KDMN

KDMN

Kadmon控股
NYSE

实时行情|Nasdaq Last Sale

5.05
-0.09
-1.75%
盘后: 5.05 0 0.00% 17:05 02/20 EST
开盘
5.17
昨收
5.14
最高
5.27
最低
4.830
成交量
203.66万
成交额
--
52周最高
5.38
52周最低
1.630
市值
8.06亿
市盈率(TTM)
-6.0851
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

KDMN 新闻

  • 巴菲特又有新头衔:任期最长的标普500企业CEO
  • 新浪美股.3小时前
  • 周四美油收高0.9% 布油上涨0.3%
  • 新浪美股.3小时前
  • 黄金期货涨0.5%录得6连涨 创7年新高
  • 新浪美股.3小时前
  • 世卫组织:国际专家组正在中国开展实地工作
  • 央视.4小时前

更多

所属板块

制药
-0.54%
制药与医学研究
-0.40%

热门股票

名称
价格
涨跌幅

KDMN 简况

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
展开

Webull提供Kadmon Holdings Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。